Table 2.
[18F]-THK5351 PET estimates in PSP-RS and HC.
| Brain region | SPM (voxels) | PSP-RS (SUVRCBL) | HC (SUVRCBL) | Difference (%) | Effect size (d) |
|---|---|---|---|---|---|
| Midbrain | 412 | 3.35 ± 0.31 | 2.49 ± 0.12 | +35 ± 12 | 4.0 |
| Frontal cortex | 2258 | 1.51 ± 0.09 | 1.18 ± 0.09 | +28 ± 7 | 3.7 |
| Globus pallidus | 436 | 3.02 ± 0.19 | 2.44 ± 0.14 | +24 ± 8 | 3.6 |
| Medulla oblongata | 50 | 2.76 ± 0.16 | 2.30 ± 0.18 | +20 ± 7 | 2.7 |
SPM- and VOI-based results of [18F]-THK5351 PET in groups of PSP patients and HC. HC, Healthy controls; PSP-RS, progressive supranuclear palsy Richardson's Syndrome; SUVR, standardized-uptake-value-ratios; CBL, cerebellum; SPM, Statistical parametric mapping; VOI, volume-of-interest.